	US 12,239,672 B2
	Mitochondrial augmentation therapy of ocular diseases
Natalie Yivgi Ohana, Haifa (IL); Uriel Halavee, Tel Aviv (IL); Shmuel Bukshpan, Ramat Hasharon (IL); Noa Sher, Haifa (IL); and Moriya Blumkin, Tel Aviv (IL)
Assigned to Minovia Therapeutics Ltd., Tirat Hacarmel (IL)
Appl. No. 17/256,527
Filed by Minovia Therapeutics Ltd., Tirat Hacarmel (IL)
PCT Filed Jul. 22, 2019, PCT No. PCT/IL2019/050822 § 371(c)(1), (2) Date Dec. 28, 2020, PCT Pub. No. WO2020/021535, PCT Pub. Date Jan. 30, 2020.
Claims priority of provisional application 62/753,943, filed on Nov. 1, 2018.
Claims priority of provisional application 62/701,783, filed on Jul. 22, 2018.
Prior Publication US 2021/0275597 A1, Sep. 9, 2021
Int. Cl. A61K 35/50 (2015.01); A61K 9/00 (2006.01); A61K 35/14 (2015.01); A61K 35/15 (2015.01); A61K 35/17 (2015.01); A61K 35/28 (2015.01); A61K 35/33 (2015.01); A61K 35/38 (2015.01); A61K 35/51 (2015.01); A61K 35/545 (2015.01); A61K 45/06 (2006.01); A61P 27/02 (2006.01)

CPC A61K 35/50 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 35/14 (2013.01); A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 35/28 (2013.01); A61K 35/33 (2013.01); A61K 35/38 (2013.01); A61K 35/51 (2013.01); A61K 35/545 (2013.01); A61K 45/06 (2013.01); A61P 27/02 (2018.01)]

20 Claims

1. A method for treating an ocular disease or an ocular disorder or a symptom thereof in a patient in need thereof, comprising administering a pharmaceutical composition to the patient, the pharmaceutical composition comprising at least about 10⁴to 10⁸human stem cells, wherein the human stem cells are enriched with human exogenous mitochondria, and wherein the ocular disease or disorder is not a mitochondrial disease or disorder caused by a pathogenic mutation in mitochondrial DNA or by a pathogenic mutation in nuclear DNA encoding a mitochondrial protein.